In vivo combination therapy with anti-PD1 or anti-CTLA4 testing

42f - Monoclonal Antibody-1

Service description

This type of therapy allows the targeting of mechanisms or pathways that have an important role in the development of cancers. In vivo tests provide a means of evaluating the effectiveness of these PD1 or CTLA4 therapies. Tumor cells are injected subcutaneously. When the size of the tumor is reached, antibody injections and tumor progression allow the effectiveness of the treatment to be monitored.

Materials to provide

  • Samples

    Further details on the project may be requested.

You will be able to exchange directly with the experts after filling in the form below.

Typical deliverables

  • Study following the specifications validated with the Expert

Get started with your in vivo combination therapy testing project

Please answer the fields below to be contacted by our team of scientists